A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 5, 2008, Pages 368-373

  Shimada, Masaaki ^a   Iwase, Hiroaki ^a   Tsuzuki, Tomoyuki ^a   Hirashima, Noboru ^a   Kobayashi, Kyoko ^a   Hibino, Yusuke ^a   Watanabe, Hisanori ^a   Ryuge, Nobumitsu ^a   Ando, Takafumi ^b   Goto, Hidemi ^b   Yagi, Yuhki ^c   Tsujikawa, Tomoyuki ^c   Andoh, Akira ^c  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cytokine; Leukocytapheresis; Ulcerative colitis

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PREDNISOLONE;

ADULT; APHERESIS; ARTICLE; BLOOD CELL COUNT; BLOOD VOLUME; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOSCOPY; FEMALE; FLOW KINETICS; HUMAN; LEUKOCYTAPHERESIS; LEUKOCYTE COUNT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

ADULT; BLOOD VOLUME; COLITIS, ULCERATIVE; COLONOSCOPY; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; LEUKAPHERESIS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBABILITY; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 53749104217     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00611.x     Document Type: Article

References (17)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 347 : 417 29.
2. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 2006 41 : 10 16.
3. Sawada K, Kusugami K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005 100 : 1362 9.
4. Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003 9 : 307 21.
5. Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 2005 50 : 767 73.
6. Yajima T, Takaishi H, Kanai T et al. Predictive factors of response to leukocytapheresis therapy for ulcerative colitis. Ther Apher 1998 2 : 115 19.
7. Andoh A, Ogawa A, Kitamura K et al. Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004 39 : 1150 7.
8. Mitsuyama K, Suzuki A, Matsumoto S et al. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005 141 : 130 40.
9. Noguchi M, Hiwatashi N, Hayakawa T, Toyota T. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher 1998 2 : 109 14.
10. Andoh A, Tsujikawa T, Inatomi O et al. Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis. Ther Apher Dial 2005 9 : 270 6.
11. Andoh A, Bamba S, Brittan M, Fujiyama Y, Wright NA. Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther 2007 114 : 94 106.
12. Yamaji K, Yang K, Tsuda H, Hashimoto H. Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher 2002 6 : 402 12.
13. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989 298 : 82 6.
14. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961 30 : 393 407.
15. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993 64 : 376 81.
16. McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998 42 : 214 19.
17. Hommes DW, van Deventer SJ. Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how, and when? Curr Opin Gastroenterol 2003 19 : 350 7.